REG - Immupharma PLC - Admission of new ordinary shares of £0.01

ImmuPharmaAnnouncement

28/06/2022 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220628:nRSb5391Qa&default-theme=true

RNS Number : 5391Q  Immupharma PLC  28 June 2022

 

 

 

 
28 June 2022

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Admission of new ordinary shares of £0.01 following share capital
reorganisation

At the AGM held earlier today, shareholders approved a resolution to
sub-divide each existing ordinary share of £0.10 nominal value in the capital
of the Company ("Existing Ordinary Shares")into one ordinary share of £0.01
each nominal value; and one deferred share of £0.09 each (these deferred
shares have no voting rights, and no practical value).

Application has today been made for 284,984,933 ordinary shares of £0.01
("New Ordinary Shares") to be admitted to trading on AIM. Admission is
expected on or around Monday 4 July 2022.

The ISIN code of the New Ordinary Shares of £0.01 nominal value will remain
the same (GB0033711010) as for the previous ordinary shares of £0.10 nominal
value.

 

Following Admission each shareholders will hold the same number of New
Ordinary Shares as they held of Existing Ordinary Shares.

 

Total Voting Rights

 

Following Admission, the Company's issued share capital will comprise
284,984,933 Ordinary Shares of £0.01 each with one voting right each. As the
Company does not hold any shares in Treasury, the total number of voting
rights in the Company is also 284,984,933 and this figure of Ordinary Shares
may be used by shareholders as the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a
change to their interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )        +44 (0) 207 206 2650

 Tim McCarthy, Chairman and Chief Executive Officer
 Lisa Baderoon, Head of Investor Relations & Non-Executive Director      + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                                 +44 (0) 203 368 3550 (about%3Ablank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                                +44 (0) 20 3650 3650

 Patrick Claridge, John Howes, Bob Pountney

 SI Capital (Joint Broker)                                               +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, Lupuzor™, within our P140 platform, is a
first-in class autophagy immunomodulator which is in Phase 3 for the treatment
of Lupus, a debilitating and potentially life threatening auto immune disease.
Preclinical analysis suggests therapeutic activity for many other autoimmune
diseases targeted through our P140 platform, that share the same autophagy
mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDZGZVVRFGZZM